Clinical Trial: EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)

Share this article:
Clinical Trial: EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)

Sponsor and Collaborators

Therapeutic Advances in Childhood Leukemia Consortium
Enzon Pharmaceuticals, Inc.

Contact
Contact: Jeannette van der Giessen, BA
323-361-8725
jvandergiessen@chla.usc.edu

Contact: Elena Eckroth
323-361-5429
eeckroth@chla.usc.edu

Principal Investigator
Study Chair: Elizabeth Raetz, MD New York University Medical Center
Study Chair: William Carroll, MD New York University Medical Center

ClinicalTrials.gov Identifier
NCT01186328

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions